Drug
PEG+Asc
PEG+Asc is a pharmaceutical drug with 3 clinical trials. Historical success rate of 100.0%.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 2 completed trials
Completion Rate
100%(2/2)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Phase Distribution
Ph not_applicable
1
33%
Ph phase_3
2
67%
Phase Distribution
0
Early Stage
0
Mid Stage
2
Late Stage
Phase Distribution3 total trials
Phase 3Large-scale testing
2(66.7%)
N/ANon-phased studies
1(33.3%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
66.7%
2 of 3 finished
Non-Completion Rate
33.3%
1 ended early
Currently Active
0
trials recruiting
Total Trials
3
all time
Status Distribution
Completed(2)
Terminated(1)
Detailed Status
Completed2
Withdrawn1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
0
Success Rate
100.0%
Most Advanced
Phase 3
Trials by Phase
Phase 32 (66.7%)
N/A1 (33.3%)
Trials by Status
withdrawn133%
completed267%
Recent Activity
0 active trials
Showing 3 of 3
completedphase_3
Effect of Simethicone on Bowel Preparation for Colonoscopy
NCT02548403
withdrawnnot_applicable
Single Center Comparison of 4 FDA Approved, Commercially Available Bowel Purgatives for Colonoscopy
NCT02124447
completedphase_3
A Randomized Prospective Trial Comparing Low-volume Bowel Preparation Methods
NCT02250196
Clinical Trials (3)
Showing 3 of 3 trials
NCT02548403Phase 3
Effect of Simethicone on Bowel Preparation for Colonoscopy
NCT02124447Not Applicable
Single Center Comparison of 4 FDA Approved, Commercially Available Bowel Purgatives for Colonoscopy
NCT02250196Phase 3
A Randomized Prospective Trial Comparing Low-volume Bowel Preparation Methods
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3